HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
An FDA advisory panel recommended allowing compounding pharmacies to manufacture peptides epitalon and semax but voted against emideltide. Amgen is challenging the FDA's proposal to withdraw its drug Tavneos from the U.S. market, citing new evidence from over 70 real-world studies.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
- STAT+: Pharmalittle: We’re reading about another FDA reversal, pharma’s M&A spree and much more
- STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more